Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BeyondSpring Inc.

Get SEC filing alerts via email and in your feed for BeyondSpring Inc.

BYSI

BeyondSpring Inc.

About BeyondSpring Inc.

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company developing innovative cancer therapies, primarily focused on Plinabulin, a novel small molecule with immunomodulating and anti-cancer properties. Plinabulin targets advanced non-small cell lung cancer and chemotherapy-induced neutropenia, enhancing immune response and safety. BeyondSpring also advances small molecule immuno-oncology agents and holds a stake in SEED Therapeutics, which develops targeted protein degradation drugs for oncology and CNS diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BeyondSpring Inc.

1
1
BeyondSpring Inc. BeyondSpring Reports $6.7 Million Net Loss in Q1 2026, No Revenue from Continuing Operations

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
BeyondSpring Inc. BeyondSpring Inc. Reports $8.7 Million Net Loss for 2025, Focuses on Cancer Therapy Development

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BeyondSpring Inc. BeyondSpring Reports Q3 2025 Financial Results with $4.9 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BeyondSpring Inc. BeyondSpring Inc. Reports Q2 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BeyondSpring Inc. BeyondSpring Reports $1.2 Million Net Income Turnaround, Focuses on R&D Investments

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BeyondSpring Inc. BeyondSpring Reports $16.7 Million Net Loss for 2024, Revenue from Discontinued Operations

Via official filing (AI summary) | about 1 year ago | 0 comments